982,848 Shares in Codexis, Inc. (NASDAQ:CDXS) Bought by CenterBook Partners LP

CenterBook Partners LP bought a new stake in Codexis, Inc. (NASDAQ:CDXS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 982,848 shares of the biotechnology company's stock, valued at approximately $4,688,000. CenterBook Partners LP owned approximately 1.21% of Codexis as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of CDXS. Tallon Kerry Patrick bought a new position in Codexis in the fourth quarter valued at about $2,018,000. Vanguard Group Inc. increased its position in Codexis by 7.5% in the 4th quarter. Vanguard Group Inc. now owns 4,463,801 shares of the biotechnology company's stock valued at $21,292,000 after acquiring an additional 311,082 shares during the period. Telemark Asset Management LLC raised its stake in shares of Codexis by 11.3% during the fourth quarter. Telemark Asset Management LLC now owns 3,000,000 shares of the biotechnology company's stock valued at $14,310,000 after acquiring an additional 303,589 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Codexis by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 1,855,514 shares of the biotechnology company's stock worth $8,853,000 after purchasing an additional 211,475 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Codexis by 484.4% in the fourth quarter. JPMorgan Chase & Co. now owns 183,906 shares of the biotechnology company's stock worth $877,000 after purchasing an additional 152,438 shares during the last quarter. Institutional investors own 78.54% of the company's stock.

Codexis Trading Down 2.6 %

NASDAQ:CDXS traded down $0.06 during trading hours on Monday, hitting $2.29. 151,715 shares of the company were exchanged, compared to its average volume of 654,909. The stock has a market capitalization of $189.70 million, a price-to-earnings ratio of -2.63 and a beta of 2.35. Codexis, Inc. has a one year low of $1.90 and a one year high of $6.08. The company has a fifty day simple moving average of $3.14 and a 200 day simple moving average of $3.88. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39.

Codexis (NASDAQ:CDXS - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.09). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The company had revenue of $21.46 million during the quarter, compared to analyst estimates of $27.41 million. Sell-side analysts expect that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.